ACA
GILD icon

Aptus Capital Advisors’s Gilead Sciences GILD Stock Holding History

Aptus Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.47M Sell
74,929
-451
-0.6% -$59.4K 0.06% 242
2026
Q1 		$10.5M Sell
75,380
-4,402
-6% -$616K 0.08% 199
2025
Q4 		$9.79M Buy
79,782
+2,702
+4% +$328K 0.07% 214
2025
Q3 		$8.56M Buy
77,080
+54,526
+242% +$6.2M 0.06% 233
2025
Q2 		$2.5M Buy
22,554
+3,879
+21% +$413K 0.02% 386
2025
Q1 		$2.09M Buy
18,675
+374
+2% +$38.6K 0.02% 387
2024
Q4 		$1.69M Buy
18,301
+10,038
+121% +$904K 0.02% 424
2024
Q3 		$693K Buy
8,263
+309
+4% +$23.6K 0.01% 477
2024
Q2 		$546K Sell
7,954
-807
-9% -$53.9K 0.01% 490
2024
Q1 		$642K Sell
8,761
-52,321
-86% -$4.02M 0.01% 460
2023
Q4 		$4.95M Sell
61,082
-80
-0.1% -$6.22K 0.14% 134
2023
Q3 		$4.58M Sell
61,162
-2,224
-4% -$171K 0.12% 140
2023
Q2 		$4.89M Buy
63,386
+59,286
+1,446% +$4.73M 0.12% 145
2023
Q1 		$340K Sell
4,100
-530
-11% -$43.9K 0.01% 372
2022
Q4 		$397K Buy
4,630
+191
+4% +$15.1K 0.01% 372
2022
Q3 		$274K Buy
+4,439
New +$280K 0.01% 397
2022
Q2 		– Sell
-2,869
Closed -$171K – 690
2022
Q1 		$171K Buy
+2,869
New +$183K ﹤0.01% 435
2020
Q3 		– Sell
-2,687
Closed -$206K – 483
2020
Q2 		$206K Sell
2,687
-1,088
-29% -$83.4K 0.01% 259
2020
Q1 		$282K Sell
3,775
-2,980
-44% -$206K 0.02% 233
2019
Q4 		$438K Sell
6,755
-23,445
-78% -$1.53M 0.03% 280
2019
Q3 		$1.91M Sell
30,200
-4,531
-13% -$296K 0.11% 130
2019
Q2 		$2.35M Buy
34,731
+3,179
+10% +$209K 0.33% 48
2019
Q1 		$2.05M Buy
31,552
+9,614
+44% +$639K 0.35% 56
2018
Q4 		$1.37M Buy
+21,938
New +$1.53M 0.36% 50

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aptus Capital Advisors's GILD Position: Q2 2026 in Review

Aptus Capital Advisors reduced its Gilead Sciences (GILD) stake by 0.6% in Q2 2026, selling an estimated $59.4K and leaving 74,929 shares worth $9.47M. The position accounts for 0.06% of the portfolio, ranked #242.

Aptus Capital Advisors first reported a position in GILD in Q4 2018 and has held it in 24 quarters since. The position peaked at $10.5M in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Aptus Capital Advisors held 74,929 shares of Gilead Sciences worth $9.47M as of Q2 2026.
  • Aptus Capital Advisors sold 451 Gilead Sciences shares in Q2 2026, an estimated $59.4K.
  • Gilead Sciences made up 0.06% of Aptus Capital Advisors's portfolio in Q2 2026, its #242 holding.
  • Aptus Capital Advisors first reported a position in Gilead Sciences in Q4 2018 and has held it in 24 quarters since.
  • Aptus Capital Advisors's Gilead Sciences position peaked at $10.5M in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.